264 related articles for article (PubMed ID: 9439546)
21. Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone.
Colin JN; Farinotti R; Fredj G; Tod M; Clavel JP; Vignon E; Dietlin F
Eur J Clin Pharmacol; 1986; 31(1):53-8. PubMed ID: 3780828
[TBL] [Abstract][Full Text] [Related]
22. Effect of beer on the plasma concentrations of uridine and purine bases.
Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Ka T; Fukuchi M; Hada T
Metabolism; 2002 Oct; 51(10):1317-23. PubMed ID: 12370853
[TBL] [Abstract][Full Text] [Related]
23. How should we treat tophaceous gout in patients with allopurinol hypersensitivity?
Grahame R; Simmonds HA; McBride MB; Marsh FP
Adv Exp Med Biol; 1998; 431():19-23. PubMed ID: 9598024
[TBL] [Abstract][Full Text] [Related]
24. [Excretion and serum concentrations of allopurinol, oxipurinol and oxipurines in combined treatment with allopurinol and benzbromarone in increasing doses].
Mertz DP; Borner K
Med Welt; 1983 Sep; 34(36):974-9. PubMed ID: 6633222
[No Abstract] [Full Text] [Related]
25. Decreased serum concentrations of 1,25(OH)2-vitamin D3 in patients with gout.
Takahashi S; Yamamoto T; Moriwaki Y; Tsutsumi Z; Yamakita J; Higashino K
Metabolism; 1998 Mar; 47(3):336-8. PubMed ID: 9500573
[TBL] [Abstract][Full Text] [Related]
26. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study.
Chou HW; Chiu HT; Tsai CW; Ting IW; Yeh HC; Huang HC; Kuo CC;
Nephrol Dial Transplant; 2018 Sep; 33(9):1620-1627. PubMed ID: 29165620
[TBL] [Abstract][Full Text] [Related]
27. Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
Chung TT; Yu KH; Kuo CF; Luo SF; Chiou MJ; Lan WC; Chen JS; Tseng WY; Hsieh AH; Wang LC
Arthritis Res Ther; 2019 Sep; 21(1):210. PubMed ID: 31533805
[TBL] [Abstract][Full Text] [Related]
28. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
Perez-Ruiz F; Calabozo M; Pijoan JI; Herrero-Beites AM; Ruibal A
Arthritis Rheum; 2002 Aug; 47(4):356-60. PubMed ID: 12209479
[TBL] [Abstract][Full Text] [Related]
29. Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol.
Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Hada T
J Rheumatol; 2001 Oct; 28(10):2294-7. PubMed ID: 11669172
[TBL] [Abstract][Full Text] [Related]
30. The use of the xanthine oxidase inhibitor, allopurinol, in the control of hyperuricaemia, gout and uric acid calculi.
Emmerson BT
Australas Ann Med; 1967 Aug; 16(3):205-14. PubMed ID: 6056609
[No Abstract] [Full Text] [Related]
31. [Uricosuric agent].
Ohno I
Nihon Rinsho; 2008 Apr; 66(4):743-7. PubMed ID: 18409525
[TBL] [Abstract][Full Text] [Related]
32. [Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol].
Ohno I; Okabe H; Yamaguchi Y; Saikawa H; Uetake D; Hikita M; Gomi H; Ichida K; Hosoya T
Nihon Jinzo Gakkai Shi; 2008; 50(4):506-12. PubMed ID: 18546882
[TBL] [Abstract][Full Text] [Related]
33. Xylitol-induced increase in the plasma concentration and urinary excretion of uridine and purine bases.
Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Yamakita J; Nakano T; Hiroishi K; Higashino K
Metabolism; 1998 Jun; 47(6):739-43. PubMed ID: 9627375
[TBL] [Abstract][Full Text] [Related]
34. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study.
Ogino K; Kato M; Furuse Y; Kinugasa Y; Ishida K; Osaki S; Kinugawa T; Igawa O; Hisatome I; Shigemasa C; Anker SD; Doehner W
Circ Heart Fail; 2010 Jan; 3(1):73-81. PubMed ID: 19933411
[TBL] [Abstract][Full Text] [Related]
35. Clinical evaluation of benzbromarone: a new uricosuric drug.
Sorensen LB; Levinson DJ
Arthritis Rheum; 1976; 19(2):183-90. PubMed ID: 1259799
[TBL] [Abstract][Full Text] [Related]
36. [Gout: physiopathology, diagnosis, course, treatment].
Chazerain P; Ziza JM
Rev Prat; 1998 Sep; 48(13):1453-6. PubMed ID: 10050628
[No Abstract] [Full Text] [Related]
37. Effect of amino acids on the plasma concentration and urinary excretion of uric acid and uridine.
Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Ohata H; Yamakita J; Nakamo T; Higashino K
Metabolism; 1999 Aug; 48(8):1023-7. PubMed ID: 10459568
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients.
Hanvivadhanakul P; Akkasilpa S; Deesomchok U
J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S40-7. PubMed ID: 12188443
[TBL] [Abstract][Full Text] [Related]
39. [Treatment of hyperuricaemia with a combination of allopurinol and benzbromaron (author's transl)].
Matzkies F; Berg G
Dtsch Med Wochenschr; 1976 Oct; 101(43):1568-70. PubMed ID: 991731
[TBL] [Abstract][Full Text] [Related]
40. Is hyperuricemia a risk factor for arteriosclerosis? Uric acid and arteriosclerosis in apolipoprotein e-deficient mice.
Wakuda H; Uchida S; Ikeda M; Tabuchi M; Akahoshi Y; Shinozuka K; Yamada S
Biol Pharm Bull; 2014; 37(12):1866-71. PubMed ID: 25451835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
